Key result
In the Dutch cohort of the APPOSITION-III trial, STEMI management showed shorter symptom-to-balloon times compared to Germany and France, with no significant difference in one-year MACE (7.7% vs 12.7% and 9.2%, p=0.112).
Population
965 STEMI patients undergoing primary percutaneous coronary intervention enrolled in the APPOSITION-III trial
Comparison
Primary PCI with STENTYS self-expandable stent… vs Geographic comparison and comparison to ESC…
Design
Cohort
Authors
Loading...
Shorter Dutch symptom-to-balloon times yielded no MACE difference; leaves open whether regional optimization improves STEMI outcomes.
Observational (n=965)
Yes
p-value: p=0.112
STEMI management in the Dutch cohort of the APPOSITION-III trial demonstrated shorter symptom-to-balloon times compared to other European cohorts and aligned well with ESC guidelines.
Vos et al. (2016) conducted an observational in ST-elevation myocardial infarction (STEMI) (n=965). Dutch STEMI management vs. German and French STEMI management was evaluated on Composite of major adverse cardiac events (MACE) at one-year post-procedure (p=0.112). In the Dutch cohort of the APPOSITION-III trial, STEMI management showed shorter symptom-to-balloon times compared to Germany and France, with no significant difference in one-year MACE (7.7% vs 12.7% and 9.2%, p=0.112).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: